Innovating.works Conecta tu I+D

Mostrando 1 al 20 de 22 resultados

SYNTHIA: Synthetic Data Generation Framework for Integrated Validation of Use Cases and AI Healthcare Applica... SYNTHIA is an ambitious collaboration between public and private institutions to facilitate the responsible use of Synthetic Data (SD) in he...
2024-08-09 - 2029-08-31 | Financiado

VICT3R: Developing and implementing VIrtual Control groups To reducE animal use in toxicology Research VICT3R, a public-private partnership running under the European Innovative Health Initiative, aims to significantly reduce the number of ani...
2024-07-26 - 2028-02-29 | Financiado

GUIDE.MRD: GUIding multi-moDal thErapies against MRD by liquid biopsies - GUIDE.MRD BRISTOL-MYERS SQUIBB COMPANY CORP participó en un HORIZON EUROPE: HORIZON-JU-IHI-2022-01-single-stage Advancing personalized approaches in cancer therapy, aiding identification and adaptation of multi-modal treatment strategies for improved o...
2023-05-17 - 2028-04-30 | Financiado

CLAIMS: CLinical impact through AI-assisted MS care BRISTOL-MYERS SQUIBB COMPANY CORP participó en un HORIZON EUROPE: HORIZON-JU-IHI-2022-01-single-stage Multiple sclerosis (MS) is a devastating immune-mediated disorder of the central nervous system. Since there is no cure available yet for MS...
2023-05-15 - 2027-05-31 | Financiado

FACILITATE: FrAmework for ClInicaL trIal participants daTA reutilization for a fully Transparent and Ethical eco... BRISTOL-MYERS SQUIBB COMPANY CORP participó en un H2020: H2020-JTI-IMI2-2020-23-two-stage FACILITATE is a project built on a patient-centered, data-driven, technological platform where an innovative data sharing and re-use process...
2021-10-11 - 2025-12-31 | Financiado

HIPPOCRATES: Health Initiatives in Psoriasis and PsOriatic arthritis ConsoRTium European States BRISTOL-MYERS SQUIBB COMPANY CORP participó en un H2020: H2020-JTI-IMI2-2020-20-two-stage Psoriatic Arthritis (PsA) is a clinically heterogeneous disease associated with diminished quality of life. Early diagnosis is challenging a...
2021-06-29 - 2026-06-30 | Financiado

PREMIER: Prioritisation and Risk Evaluation of Medicines in the EnviRonment BRISTOL-MYERS SQUIBB COMPANY CORP participó en un H2020: H2020-JTI-IMI2-2019-17-two-stage There are around 1900 active pharmaceutical ingredients (APIs) in use, yet the environmental risks of only a small proportion of these has b...
2020-06-24 - 2026-08-31 | Financiado

IDEA-FAST: Identifying Digital Endpoints to Assess FAtigue Sleep and acTivities in daily living in Neurodegene... BRISTOL-MYERS SQUIBB COMPANY CORP participó en un H2020: H2020-JTI-IMI2-2018-15-two-stage Fatigue and sleep disturbances are two common and disabling symptoms that affect patients with neurodegenerative disorders (NDD) and immune-...
2019-12-18 - 2026-04-30 | Financiado

3TR: Identification of the Molecular Mechanisms of non response to Treatments Relapses and Remission in... BRISTOL-MYERS SQUIBB COMPANY CORP participó en un H2020: H2020-JTI-IMI2-2018-14-two-stage 3TR is a transdisciplinary consortium made of experts in all areas of medicine, basic sciences and bioinformatics from academic institutions...
2019-08-22 - 2026-08-31 | Financiado

ConcePTION: Building an ecosystem for better monitoring and communicating of medication safety in pregnancy and... BRISTOL-MYERS SQUIBB COMPANY CORP participó en un H2020: H2020-JTI-IMI2-2017-13-two-stage ConcePTION partners have united around a shared vision that we have a societal obligation to radically and rapidly reduce uncertainty about...
2019-05-06 - 2024-12-31 | Financiado

NECESSITY: NEw Clinical Endpoints in primary Sjögren s Syndrome an Interventional Trial based on stratifYing p... BRISTOL-MYERS SQUIBB COMPANY CORP participó en un H2020: H2020-JTI-IMI2-2017-12-two-stage Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease (AID) involving 0.5 to 3/1000 persons. The disease affects exocrine glands...
2018-12-18 - 2025-12-31 | Financiado

LITMUS: Liver Investigation Testing Marker Utility in Steatohepatitis BRISTOL-MYERS SQUIBB COMPANY CORP participó en un H2020: H2020-JTI-IMI2-2016-09-two-stage Strongly associated with the epidemics of obesity and type 2 diabetes that are testing healthcare systems worldwide, Non-Alcoholic Fatty Liv...
2017-10-09 - 2024-02-29 | Financiado

RTCure: Rheuma Tolerance for Cure BRISTOL-MYERS SQUIBB COMPANY CORP participó en un H2020: H2020-JTI-IMI2-2016-09-two-stage In line with IMI2 goals for improved therapies and precision medicine, the aim of this proposal is to prevent and treat RA or its progressio...
2017-08-25 - 2023-08-31 | Financiado

ADAPT-SMART: Accelerated Development of Appropriate Patient Therapies a Sustainable Multi stakeholder Approach... BRISTOL-MYERS SQUIBB COMPANY CORP participó en un H2020: H2020-JTI-IMI2-2015-04-two-stage-Master Progress in the life sciences and related technologies offer great potential for therapeutic benefits to patients in need. However, major ad...
2015-09-02 - 2018-04-30 | Financiado

GETREAL: Incorporating real life clinical data into drug development BRISTOL-MYERS SQUIBB COMPANY CORP participó en un FP7: When a new medicine reaches the market, it is accompanied by an extensive data package that provides information about the safety and effica...
Financiado

MIP-DILI: Mechanism Based Integrated Systems for the Prediction of Drug Induced Liver Injury BRISTOL-MYERS SQUIBB COMPANY CORP participó en un FP7: The current test systems employed by Industry are poorly predictive for Drug induced liver injury (DILI). The ‘MIP-DILI’ project will addres...
Financiado

ECHOUTCOME: European Consortium in Healthcare Outcomes and cost benefit research BRISTOL-MYERS SQUIBB COMPANY CORP participó en un FP7: ECHOUTCOME is an interdisciplinary European research platform with the aim of assessing methodological properties of Healthcare Outcome and...
Financiado

BTCURE: BeTheCuRE BRISTOL-MYERS SQUIBB COMPANY CORP participó en un FP7: BTCure is based on the recognition that RA is a heterogeneous disease where a major subset involves adaptive immunity, and that animal model...
Financiado

GLYCOHIT: Glycomics by High throughput Integrated Technologies BRISTOL-MYERS SQUIBB COMPANY CORP participó en un FP7: Protein glycosylation is a post-translational phenomenon that is involved in most physiological and disease processes including cancer. Most...
Financiado

ORBITO: Oral biopharmaceutics tools BRISTOL-MYERS SQUIBB COMPANY CORP participó en un FP7: The OrBiTo project will deliver novel methods and a framework for rational application of predictive biopharmaceutics tools for oral drug de...
Financiado

BMS